{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:40Z","timestamp":1793316280867,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1093\/neuonc\/nou328","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T23:55:42Z","timestamp":1419033342000},"page":"1261-1269","source":"Crossref","is-referenced-by-count":152,"title":["A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K"],"prefix":"10.1093","volume":"17","author":[{"given":"Daniel J.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Keith","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Peller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon H.","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"McGraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt A.","family":"Jaeckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"issue":"(7)","key":"key\n\t\t\t\t20170522210351_NOU328C1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","article-title":"Regulation of translation initiation by FRAP\/mTOR","volume":"15","author":"Gingras","year":"2001","journal-title":"Genes Dev"},{"key":"key\n\t\t\t\t20170522210351_NOU328C2","first-page":"299","article-title":"mTOR as a positive regulator of tumor cell responses to hypoxia","volume":"279","author":"Abraham","year":"2004","journal-title":"Curr Top Microbiol Immunol."},{"issue":"(2)","key":"key\n\t\t\t\t20170522210351_NOU328C3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"issue":"(14)","key":"key\n\t\t\t\t20170522210351_NOU328C4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"issue":"(5712)","key":"key\n\t\t\t\t20170522210351_NOU328C5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"(7459)","key":"key\n\t\t\t\t20170522210351_NOU328C6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nature12297","article-title":"mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function","volume":"499","author":"Zeng","year":"2013","journal-title":"Nature"},{"issue":"(6)","key":"key\n\t\t\t\t20170522210351_NOU328C7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11523-013-0303-8","article-title":"New agents in renal cell carcinoma","volume":"9","author":"Dabney","year":"2014","journal-title":"Target Oncol."},{"issue":"(5)","key":"key\n\t\t\t\t20170522210351_NOU328C9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s11940-013-0249-2","article-title":"Management of CNS-related disease manifestations in patients with tuberous sclerosis complex","volume":"15","author":"Krueger","year":"2013","journal-title":"Curr Treat Options Neurol"},{"issue":"(24)","key":"key\n\t\t\t\t20170522210351_NOU328C10","first-page":"7291","article-title":"Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy","volume":"62","author":"Eshleman","year":"2002","journal-title":"Cancer Res"},{"issue":"(10)","key":"key\n\t\t\t\t20170522210351_NOU328C11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1593\/neo.05361","article-title":"Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells","volume":"7","author":"Rao","year":"2005","journal-title":"Neoplasia"},{"issue":"(5)","key":"key\n\t\t\t\t20170522210351_NOU328C12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/153303460700600510","article-title":"The role of mTOR inhibition in augmenting radiation induced autophagy","volume":"6","author":"Jaboin","year":"2007","journal-title":"Technol Cancer Res Treat"},{"key":"key\n\t\t\t\t20170522210351_NOU328C13","doi-asserted-by":"crossref","first-page":"454957","DOI":"10.1155\/2012\/454957","article-title":"The clinical and prognostic significance of activated Akt-mTOR pathway in human astrocytomas","volume":"2012","author":"El Habr","year":"2012","journal-title":"Neurol Res Int"},{"issue":"(23)","key":"key\n\t\t\t\t20170522210351_NOU328C14","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"issue":"(9)","key":"key\n\t\t\t\t20170522210351_NOU328C15","first-page":"1210","article-title":"Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells","volume":"43","author":"Rasey","year":"2002","journal-title":"J Nucl Med"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0969-8051(02)00286-X","article-title":"Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines","volume":"29","author":"Toyohara","year":"2002","journal-title":"Nucl Med Biol"},{"issue":"(1)","key":"key\n\t\t\t\t20170522210351_NOU328C17","first-page":"114","article-title":"Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3\u2032-deoxy-3\u2032-18F-fluorothymidine PET","volume":"46","author":"Waldherr","year":"2005","journal-title":"J Nucl Med"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2010.08.001","article-title":"PET for radiation treatment planning of brain tumours","volume":"96","author":"Grosu","year":"2010","journal-title":"Radiother Oncol"},{"issue":"(6)","key":"key\n\t\t\t\t20170522210351_NOU328C19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/RCT.0b013e3182345b0e","article-title":"Diagnostic usefulness of 3\u2032-deoxy-3\u2032-[18F]fluorothymidine positron emission tomography in recurrent brain tumor","volume":"35","author":"Hong","year":"2011","journal-title":"J Comput Assist Tomogr"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11307-010-0361-6","article-title":"[18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas","volume":"13","author":"Rueger","year":"2011","journal-title":"Mol Imaging Biol"},{"issue":"(1)","key":"key\n\t\t\t\t20170522210351_NOU328C21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2967\/jnumed.111.092387","article-title":"3\u2032-Deoxy-3\u2032-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab","volume":"53","author":"Schwarzenberg","year":"2012","journal-title":"J Nucl Med"},{"issue":"(10)","key":"key\n\t\t\t\t20170522210351_NOU328C22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2967\/jnumed.109.073288","article-title":"18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model","volume":"51","author":"Aide","year":"2010","journal-title":"J Nucl Med"},{"issue":"(2)","key":"key\n\t\t\t\t20170522210351_NOU328C23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijrobp.2010.05.064","article-title":"North Central Cancer Treatment Group phase I trial N057 K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme","volume":"81","author":"Sarkaria","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"(11)","key":"key\n\t\t\t\t20170522210351_NOU328C24","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"(12)","key":"key\n\t\t\t\t20170522210351_NOU328C25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/MNM.0b013e32832ee93b","article-title":"Molecular PET and PET\/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation","volume":"30","author":"Barwick","year":"2009","journal-title":"Nucl Med Commun"},{"issue":"(11)","key":"key\n\t\t\t\t20170522210351_NOU328C26","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/nm.3328","article-title":"Coordinate activation of Shh and PI3 K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities","volume":"19","author":"Gruber Filbin","year":"2013","journal-title":"Nat Med"},{"issue":"(15)","key":"key\n\t\t\t\t20170522210351_NOU328C27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"issue":"(2)","key":"key\n\t\t\t\t20170522210351_NOU328C28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2006.01.021","article-title":"TORgeting oncogene addiction for cancer therapy","volume":"9","author":"Choo","year":"2006","journal-title":"Cancer Cell"},{"issue":"(38)","key":"key\n\t\t\t\t20170522210351_NOU328C29","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1073\/pnas.1019012108","article-title":"Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC\/Rheb-independent manner","volume":"108","author":"Banerjee","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11910-012-0269-4","article-title":"Molecular therapies for tuberous sclerosis and neurofibromatosis","volume":"12","author":"Franz","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"(9)","key":"key\n\t\t\t\t20170522210351_NOU328C31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t20170522210351_NOU328C32","first-page":"211","article-title":"Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex","volume":"7","author":"Franz","year":"2013","journal-title":"Biologics."},{"issue":"(34)","key":"key\n\t\t\t\t20170522210351_NOU328C33","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J Clin Oncol"},{"issue":"(6)","key":"key\n\t\t\t\t20170522210351_NOU328C34","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1007\/s10637-011-9775-5","article-title":"A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study","volume":"30","author":"Mason","year":"2012","journal-title":"Invest New Drugs"},{"issue":"(17)","key":"key\n\t\t\t\t20170522210351_NOU328C35","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.28142","article-title":"A prospective, phase 1\/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor","volume":"119","author":"Chan","year":"2013","journal-title":"Cancer"},{"issue":"(4)","key":"key\n\t\t\t\t20170522210351_NOU328C36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/COC.0b013e31827b45d4","article-title":"Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675","volume":"37","author":"Dronca","year":"2014","journal-title":"Am J Clin Oncol."},{"issue":"(1)","key":"key\n\t\t\t\t20170522210351_NOU328C37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/RLI.0b013e3181c02ed5","article-title":"Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging","volume":"45","author":"Bauknecht","year":"2010","journal-title":"Invest Radiol"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-012-0843-2","article-title":"Assessment of intra-observer variability in measurement of high-grade brain tumors","volume":"108","author":"Provenzale","year":"2012","journal-title":"J Neurooncol"},{"issue":"(4)","key":"key\n\t\t\t\t20170522210351_NOU328C39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00280-009-1068-8","article-title":"Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents","volume":"65","author":"O'Reilly","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"(3)","key":"key\n\t\t\t\t20170522210351_NOU328C40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-007-9371-x","article-title":"Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells","volume":"84","author":"Tanaka","year":"2007","journal-title":"J Neurooncol"},{"issue":"(5)","key":"key\n\t\t\t\t20170522210351_NOU328C41","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ijrobp.2013.04.036","article-title":"RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma","volume":"86","author":"Chinnaiyan","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"(18)","key":"key\n\t\t\t\t20170522210351_NOU328C42","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"issue":"(6)","key":"key\n\t\t\t\t20170522210351_NOU328C43","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522210351_NOU328C44","article-title":"Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2\u2013negative (HER2\u2013) advanced breast cancer (BC): overall survival results from BOLERO-2","author":"Piccart-Gebhart","year":"2014"},{"issue":"(2)","key":"key\n\t\t\t\t20170522210351_NOU328C45","first-page":"e38","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"issue":"(6)","key":"key\n\t\t\t\t20170522210351_NOU328C46","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"(5)","key":"key\n\t\t\t\t20170522210351_NOU328C47","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/0008-5472.CAN-12-3923","article-title":"Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience","volume":"73","author":"Yao","year":"2013","journal-title":"Cancer Res"},{"issue":"(12)","key":"key\n\t\t\t\t20170522210351_NOU328C48","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1158\/1078-0432.CCR-07-4152","article-title":"PTEN loss does not predict for response to RAD001 (everolimus) in a glioblastoma orthotopic xenograft test panel","volume":"14","author":"Yang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170522210351_NOU328C49","doi-asserted-by":"crossref","article-title":"PTEN assessment and PI3K\/mTOR inhibitors: importance of simultaneous assessment of MAPK pathway aberrations","author":"Janku","DOI":"10.1200\/jco.2012.30.15_suppl.10510"},{"key":"key\n\t\t\t\t20170522210351_NOU328C50","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.lba509","article-title":"Correlation of molecular alterations with efficacy of everolimus in hormone receptor\u2013positive, HER2-negative advanced breast cancer: results from BOLERO-2","author":"Hortobagyi","year":"2013"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/17\/9\/1261\/17430352\/nou328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:24:10Z","timestamp":1598570650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nou328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,12,18]]},"published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nou328","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}